2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 16: December 6, 2023 - JAK Inhibitors and Wound Care Update
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, December 6, 2023
8 PM ET / 5 PM PT
JAK Inhibitors: Who is Afraid of the Big Black Box?
What's New in Wound Care
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 7, 2023
December 7, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Evaluate data concerning side effects of JAK inhibitors
Assess new treatments and their on label and off label use
Understand the benefits of single use Negative Pressure Wound Therapy
Utilize novel skin grafting techniques in the clinical practice
Intended Audience
Faculty
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV
Robert Kirsner, MD
Chairman and Harvey Blank Professor
Dr. Phillip Frost Department of Derm & Cutaneous Surgery
Miller School of Medicine - University of Miami
Miami, FL
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
Advisory Board: Abbvie, Molnklycke, Organogenesis, Pfizer, Urgo
Grant/Research Support: Hoth
Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.